MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) today announced that the results of the Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) for advanced prostate cancer will be presented during a late breaking oral presentation at the 2008 Annual Meeting of the American Association for Cancer Research being held in San Diego April 12 - 16.
